Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 71610-289

6 FDA label images from Aphena Pharma Solutions - Tennessee, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 71610-289). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle Label 250 mg (71610 0289 30)

Bottle Label 250 mg (71610 0289 30)
Label for Divalproex Sodium extended release tablets, 250 mg strength, oral dosage form. The label indicates a package of 30 tablets, with manufacturer Aurobindo Pharma Limited and the labeler Aphena Pharma Solutions - Tennessee, LLC. Storage instructions and handling precautions are printed, including recommended temperature and dispensing guidelines. The label shows barcode, lot number, NDC 71610-0289, and expiration date information.*
FDA Label Image

Aphena Pharma Solutions (TN)

Aphena Pharma Solutions (TN)
FDA Label Image

Figure 1 (Divalproex Fig1)

Figure 1 (Divalproex Fig1)
A cumulative distribution graph comparing percent reduction in CPS rate between Divalproex Sodium Delayed-Release Tablets and placebo. The vertical axis shows percentage change from worsening to improvement, while the horizontal axis represents percent of patients from 100 to 0, illustrating treatment effects on patient outcomes.*
FDA Label Image

Figure 2 (Divalproex Fig2)

Figure 2 (Divalproex Fig2)
Figure 2 is a cumulative distribution graph showing percentage reduction in CPS rate versus percentage of patients for high and low dose Divalproex sodium delayed-release tablets. The vertical axis indicates improvement or worsening in CPS rate, and the horizontal axis represents the percentage of patients, comparing the two dosage groups.*
FDA Label Image

Fig-3 (Divalproex Fig3)

Fig-3 (Divalproex Fig3)
A bar chart comparing the effect of Placebo versus Divalproex Sodium Extended-Release Tablets. The vertical axis shows a quantitative measure ranging from 0 to 1.2, with the Divalproex Sodium bar reaching 1.2 and the Placebo bar reaching 0.6. A statistical significance indicator (p=0.006) is noted above the Divalproex Sodium bar.*
FDA Label Image

Chemical Structure (Divalproex Str)

Chemical Structure (Divalproex Str)
Chemical structure diagram of divalproex sodium, showing the polymeric form with repeating units featuring carbon chains, carboxyl groups, and sodium ions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.